- Home
- FURY vs JSPR Comparison
FURY vs JSPR Comparison
Compare FURY & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- JSPR
- Stock Information
- Founded
- FURY 2008
- JSPR 2018
- Country
- FURY Canada
- JSPR United States
- Employees
- FURY N/A
- JSPR N/A
- Industry
- FURY Precious Metals
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- JSPR Health Care
- Exchange
- FURY Nasdaq
- JSPR Nasdaq
- Market Cap
- FURY 84.1M
- JSPR 68.4M
- IPO Year
- FURY N/A
- JSPR N/A
- Fundamental
- Price
- FURY $0.72
- JSPR $2.54
- Analyst Decision
- FURY Strong Buy
- JSPR Buy
- Analyst Count
- FURY 2
- JSPR 11
- Target Price
- FURY $1.40
- JSPR $28.00
- AVG Volume (30 Days)
- FURY 1.2M
- JSPR 443.9K
- Earning Date
- FURY 11-11-2025
- JSPR 11-06-2025
- Dividend Yield
- FURY N/A
- JSPR N/A
- EPS Growth
- FURY N/A
- JSPR N/A
- EPS
- FURY N/A
- JSPR N/A
- Revenue
- FURY N/A
- JSPR N/A
- Revenue This Year
- FURY N/A
- JSPR N/A
- Revenue Next Year
- FURY N/A
- JSPR N/A
- P/E Ratio
- FURY N/A
- JSPR N/A
- Revenue Growth
- FURY N/A
- JSPR N/A
- 52 Week Low
- FURY $0.35
- JSPR $2.22
- 52 Week High
- FURY $0.89
- JSPR $26.05
- Technical
- Relative Strength Index (RSI)
- FURY 53.60
- JSPR 50.33
- Support Level
- FURY $0.70
- JSPR $2.41
- Resistance Level
- FURY $0.88
- JSPR $2.65
- Average True Range (ATR)
- FURY 0.07
- JSPR 0.15
- MACD
- FURY 0.00
- JSPR 0.03
- Stochastic Oscillator
- FURY 42.54
- JSPR 62.50
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.